Skip to main content
. Author manuscript; available in PMC: 2012 Jun 10.
Published in final edited form as: Cell. 2011 Jun 10;145(6):863–874. doi: 10.1016/j.cell.2011.05.020

Figure 5.

Figure 5

JM6 increases brain KYNA levels in a mouse model of AD. (A) Compared to WT mice, cortical KYNA levels are significantly reduced in APPtg mice, and the deficit is normalized by JM6 treatment (75 mg/kg/day p.o. for 120 days); (B) Plasma KYNA measurements in the same three groups show a similar pattern as in the brain. (C-F) No group differences are seen in cortical KMO activity (C), 3-HK levels (D) and QUIN levels (E), as well as in plasma QUIN levels (F). Values are means ± s.e.m. [n = 5–15 per group, except APPtg controls in (B) (n = 3)]. *p<0.05, **p<0.01 (t-test); ns: not significant.